Universe Pharmaceuticals INC (NASDAQ:UPC) experienced a dramatic surge on Thursday, with shares skyrocketing 331.76% to $12.78 in late trading. The rally came after the company disclosed a significant patent acquisition deal, though the transaction structure has raised eyebrows among investors due to the potential for substantial share dilution.
Trading volume exploded to 52.8 million shares, approximately 81 times the company's outstanding share count of just 651,310 shares, according to StockAnalysis. The surge outpaced broader market gains, with the S&P 500, Nasdaq, and biotech ETFs all rising modestly.
Patent Acquisition Details
According to a June 26 SEC filing, Universe Pharmaceuticals plans to issue 4.376552 million Class A shares to acquire Best Praise International for $10.751 million. The implied price per consideration share is approximately $2.46, representing a steep discount to the current market price of $12.78. At that price, the block of shares would be valued at $55.9 million, or 5.2 times the agreed purchase price.
The deal involves five patents in China covering drug compounds and delivery technologies related to age-related diseases, neurodegenerative disorders, and cardiovascular applications. CEO Gang Lai stated the patents will expand the company's pharmaceutical capabilities and broaden its product pipeline.
Financial Context and Concerns
The acquisition comes as Universe Pharmaceuticals faces significant financial headwinds. For fiscal year 2025, the company reported revenue of $17.858 million, down 22.4% from the prior year, and a net loss of $3.672 million. Research and development spending plummeted 77.8% to just $671,761, raising questions about the company's commitment to innovation.
The $10.751 million deal price represents about 60% of fiscal 2025 revenue and roughly 16 times the company's annual R&D expenditure. This has led some analysts to question the strategic fit and valuation of the transaction.
Regulatory Hurdles and Risks
The share issuance remains subject to several conditions, including SEC and Nasdaq approval, a legal opinion on the patents from Chinese authorities, and a new valuation report. The agreement includes a 120-day window for closing, with either party able to walk away if conditions are not met, unless both agree to an extension.
The newly issued shares will be restricted, limiting immediate liquidity. However, the potential for future dilution remains a key concern for existing shareholders, given that the new shares represent 6.7 times the current float.
Market participants are closely watching for further developments, including regulatory approvals and any additional details on the patent portfolio's commercial potential. The stock's extreme volatility and the deal's structure suggest significant uncertainty ahead for Universe Pharmaceuticals.
